By the ZIVOLABS Medical Team · Updated April 2026 · 6 min read

The most common concern patients raise about generic semaglutide is simple: is it actually as good? When Ozempic costs ₹25,000/month and the Indian generic costs ₹4,999/month, the price gap feels suspicious. This article addresses that concern directly — with the science, not the marketing.

What "generic" actually means

A generic drug is not a copy. It is a reproduction of the same active molecule, manufactured by a different company once the original patent expires or exclusivity lapses.

The regulatory approval process for a generic drug requires the manufacturer to demonstrate bioequivalence to the reference product. Bioequivalence means the generic must deliver the same amount of the active molecule into the bloodstream at the same rate as the original. Not similar — the same. The standard regulatory requirement is that the generic's pharmacokinetic profile (how the drug behaves in the body) must fall within 80–125% of the reference product's profile.

In practice, well-manufactured generics typically fall within 95–105% — they are, for clinical purposes, indistinguishable from the original.

This is not a new or theoretical standard. Billions of patients globally take generic medications every day — generic metformin, generic atorvastatin, generic amlodipine — with no clinically meaningful difference from the branded original. The Indian pharmaceutical industry is one of the largest producers of generic medications in the world, supplying major markets including the US, UK, and Europe.

Specifically for semaglutide: what DCGI approval requires

For Semasize (Alkem Laboratories) and Semanat (Natco Pharma) to receive DCGI approval, they were required to demonstrate:

Bioequivalence to the reference product (Ozempic). Pharmacokinetic studies showing that the semaglutide from Alkem's or Natco's formulation reaches the same blood concentration, at the same rate, as Novo Nordisk's semaglutide.

Manufacturing quality under GMP standards. The manufacturing facility, processes, raw materials, and quality control systems must meet Good Manufacturing Practice standards as assessed by DCGI inspection.

Stability. The product must demonstrate that it maintains its quality and potency throughout its shelf life under specified storage conditions.

These are not paperwork requirements — they are laboratory and clinical data submissions reviewed by India's central drug regulator.

Are Alkem and Natco credible manufacturers?

Yes. Substantially so.

Alkem Laboratories is a top-10 Indian pharmaceutical company by revenue, with manufacturing facilities that supply medications to the US (USFDA-approved facilities), Europe, and Australia. They manufacture both domestic-market and export-quality products under international regulatory standards. Semasize is a domestic product from a company that manufactures for regulated international markets.

Natco Pharma is a respected mid-size Indian pharmaceutical company with a strong track record in oncology and specialty medications. Natco has been involved in challenging pharmaceutical patents in India on public health grounds — including anti-cancer medications — and is known for producing quality generics of complex molecules.

Neither company is an unknown startup. Both have track records, inspected facilities, and regulatory approvals across multiple markets.

Why is the price so much lower?

This is the question the price gap naturally raises — and it has a clear answer.

No R&D cost recovery. Novo Nordisk spent billions developing and trialling semaglutide over more than a decade. The branded price partially recovers that investment. Generic manufacturers do not bear this cost — they conduct bioequivalence studies, not phase 1–3 clinical trials.

No import costs. Ozempic is manufactured in Denmark and imported into India. Semasize and Semanat are manufactured in India, eliminating import duties and international logistics costs.

No brand premium. Established pharmaceutical brands command a pricing premium that reflects not just the product but the brand equity built over years of marketing and physician relationships. Generics do not carry this premium.

Volume efficiency. Indian generic manufacturers operate at scale, often producing medications at lower per-unit cost than branded manufacturers.

The lower price reflects lower costs at every stage of the value chain — not lower quality.

What the medical community says

Indian endocrinologists and metabolic specialists who have been prescribing generic semaglutide since its DCGI approval are reporting clinical outcomes consistent with the branded product. There is no credible clinical evidence or case series suggesting inferior efficacy or safety in the DCGI-approved Indian generics.

This is consistent with what we know from decades of generic medication use globally. The narrative that "generics are lower quality" is not supported by the regulatory science or clinical evidence — it is a perception that benefits branded manufacturers and is not grounded in pharmacology.

The one real risk: unregulated products

The concern about generic semaglutide quality is valid — but it is aimed at the wrong target. The real quality risk is not from DCGI-approved generics. It is from unregulated, unapproved products:

• Compounded semaglutide from unregulated pharmacies

• Products sold via Instagram, WhatsApp, or unregistered websites

• Grey-market imports without clear manufacturer identification or cold-chain history

• Products with no batch number, no expiry date, no DCGI registration number

These carry genuine quality and safety risks. They are not the same thing as DCGI-approved generic semaglutide from Alkem or Natco.

When you receive semaglutide through ZIVOLABS, it comes from a licensed pharmacy, dispensed against a valid prescription, from a named DCGI-approved manufacturer. This is not the same product as something bought from an unverified online seller.

Side-by-side: Ozempic vs Indian generics

Frequently asked questions

Can I ask my doctor to prescribe Ozempic instead? Your doctor can prescribe by brand name if you request it — but given the bioequivalence and the price difference, most Indian metabolic specialists recommend generic semaglutide. There is no clinical reason to pay 4–6x more for the same molecule.

What if I was on Ozempic abroad and am now switching to the Indian generic? You can switch without concern about clinical efficacy. You are continuing the same molecule at the same dose — the source changes, not the treatment.

How do I know the generic I received is genuine? Products dispensed through ZIVOLABS carry the manufacturer's name, batch number, manufacturing date, expiry date, and DCGI registration. If you receive a product without these identifiers, contact ZIVOLABS immediately.

The bottom line

DCGI-approved generic semaglutide (Semasize, Semanat) is bioequivalent to Ozempic. The lower price reflects lower costs — not lower quality. The regulatory standard is identical. The molecule is identical. The clinical expectation is the same.

[Start your ZIVOLABS health assessment →]

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified doctor before starting any new treatment.